JP2024531728A5 - - Google Patents
Info
- Publication number
- JP2024531728A5 JP2024531728A5 JP2024516476A JP2024516476A JP2024531728A5 JP 2024531728 A5 JP2024531728 A5 JP 2024531728A5 JP 2024516476 A JP2024516476 A JP 2024516476A JP 2024516476 A JP2024516476 A JP 2024516476A JP 2024531728 A5 JP2024531728 A5 JP 2024531728A5
- Authority
- JP
- Japan
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB2113104.0A GB202113104D0 (en) | 2021-09-14 | 2021-09-14 | Antagonist of pcsk9 |
| GB2113104.0 | 2021-09-14 | ||
| GBGB2207239.1A GB202207239D0 (en) | 2022-05-18 | 2022-05-18 | Treatment of cardiovascular disease 2 |
| GB2207239.1 | 2022-05-18 | ||
| PCT/EP2022/075355 WO2023041508A2 (en) | 2021-09-14 | 2022-09-13 | Treatment of cardiovascular disease |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024531728A JP2024531728A (ja) | 2024-08-29 |
| JPWO2023041508A5 JPWO2023041508A5 (https=) | 2025-07-23 |
| JP2024531728A5 true JP2024531728A5 (https=) | 2025-07-23 |
Family
ID=83691543
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024516476A Pending JP2024531728A (ja) | 2021-09-14 | 2022-09-13 | 心血管疾患の処置 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20250283076A1 (https=) |
| EP (1) | EP4402263A2 (https=) |
| JP (1) | JP2024531728A (https=) |
| CA (1) | CA3229020A1 (https=) |
| WO (1) | WO2023041508A2 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL312811A (en) | 2021-11-16 | 2024-07-01 | Shanghai Argo Biopharmaceutical Co Ltd | Composition and method for inhibiting angiotensinogen (agt) protein expression |
| TW202345865A (zh) * | 2022-01-24 | 2023-12-01 | 大陸商上海舶望製藥有限公司 | 抑制LPA(Apo(a))蛋白表達的組合物和方法 |
| EP4680740A1 (en) * | 2023-03-14 | 2026-01-21 | Argonaute Rna Limited | Conjugate comprising a double stranded rna molecule linked to a single stranded dna molecule |
| WO2024228030A2 (en) * | 2023-05-04 | 2024-11-07 | Argonaute RNA Limited | Dual silencing |
| WO2024245151A1 (zh) * | 2023-05-26 | 2024-12-05 | 维亚臻生物技术（苏州）有限公司 | 一种用于代谢疾病的双链核苷酸化合物及其应用 |
| AU2024321098A1 (en) * | 2023-08-09 | 2026-03-19 | Beijing Foyou Pharma Co., Ltd | Sirna for inhibiting dgat2 gene expression, sirna conjugate or prodrug and pharmaceutical composition thereof, and use thereof |
| WO2025040139A1 (zh) * | 2023-08-23 | 2025-02-27 | 云合智药（苏州）生物科技有限公司 | 用于抑制二酰甘油-O-酰基转移酶2表达的RNAi剂及其应用 |
| WO2025103391A1 (zh) * | 2023-11-15 | 2025-05-22 | 北京加科瑞康医药科技有限公司 | 用于抑制lpa的基因表达的sirna，含其的组合物及其用途 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001064008A2 (en) | 2000-03-03 | 2001-09-07 | Smithkline Beecham Biologicals S.A. | Vaccine for the treatment of artherosclerosis |
| GB0121171D0 (en) | 2001-08-31 | 2001-10-24 | Glaxosmithkline Biolog Sa | Vaccine |
| GB0305794D0 (en) | 2003-03-13 | 2003-04-16 | Glaxosmithkline Biolog Sa | Vaccine |
| US7825235B2 (en) | 2003-08-18 | 2010-11-02 | Isis Pharmaceuticals, Inc. | Modulation of diacylglycerol acyltransferase 2 expression |
| WO2005045035A2 (en) | 2003-10-23 | 2005-05-19 | Sirna Therapeutics, Inc. | RNA INTERFERENCE MEDIATED INHIBITION OF NOGO AND NOGO RECEPTOR GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| US8067572B2 (en) * | 2005-05-25 | 2011-11-29 | The University Of York | Hybrid interfering RNA |
| EP2023940B1 (en) | 2006-05-05 | 2011-06-22 | Isis Pharmaceuticals, Inc. | Compounds and methods for modulating expression of sglt2 |
| AU2007275365A1 (en) * | 2006-07-17 | 2008-01-24 | Sirna Therapeutics Inc. | RNA interference mediated inhibition of Proprotein Convertase Subtilisin Kexin 9 (PCSK9) gene expression using short interfering nucleic acid (siNA) |
| ES2804764T3 (es) * | 2009-06-01 | 2021-02-09 | Halo Bio Rnai Therapeutics Inc | Polinucleótidos para la interferencia de ARN multivalente, composiciones y métodos de uso de los mismos |
| WO2012058693A2 (en) * | 2010-10-29 | 2012-05-03 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibition of pcsk9 genes |
| US10125369B2 (en) * | 2012-12-05 | 2018-11-13 | Alnylam Pharmaceuticals, Inc. | PCSK9 iRNA compositions and methods of use thereof |
| DK2991656T3 (da) | 2013-05-01 | 2020-03-23 | Ionis Pharmaceuticals Inc | Sammensætninger og fremgangsmåder til modulering af apolipoprotein c-iii-ekspression |
| WO2014205449A2 (en) | 2013-06-21 | 2014-12-24 | Isis Pharmaceuticals, Inc. | Compounds and methods for modulating apolipoprotein c-iii expression for improving a diabetic profile |
| JOP20160211B1 (ar) | 2015-10-01 | 2021-08-17 | Arrowhead Pharmaceuticals Inc | تراكيب وأساليب لتثبيط تعبير جيني للـ lpa |
| BR112019010057A2 (pt) | 2016-11-16 | 2019-09-03 | Purdue Research Foundation | composição, método para suprimir a ingestão de comida, sequência de shrna, método de inibição da síntese de ácidos graxos |
| MX2020004897A (es) | 2017-11-13 | 2020-10-05 | Silence Therapeutics Gmbh | Acidos nucleicos para inhibir la expresion de lpa en una celula. |
| BR112021009213A2 (pt) * | 2018-11-13 | 2021-08-10 | Silence Therapeutics Gmbh | ácidos nucleicos para inibição da expressão de lpa em uma célula |
| US20230027604A1 (en) * | 2019-07-02 | 2023-01-26 | Argonaute RNA Limited | Apolipoprotein b antagonist |
| US20230078200A1 (en) * | 2019-12-09 | 2023-03-16 | Amgen Inc. | RNAi CONSTRUCTS AND METHODS FOR INHIBITING LPA EXPRESSION |
| US20230183694A1 (en) * | 2020-03-16 | 2023-06-15 | Argonaute RNA Limited | Antagonist of pcsk9 |
-
2022
- 2022-09-13 WO PCT/EP2022/075355 patent/WO2023041508A2/en not_active Ceased
- 2022-09-13 JP JP2024516476A patent/JP2024531728A/ja active Pending
- 2022-09-13 EP EP22789482.1A patent/EP4402263A2/en active Pending
- 2022-09-13 US US18/691,775 patent/US20250283076A1/en active Pending
- 2022-09-13 CA CA3229020A patent/CA3229020A1/en active Pending